Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
Price Target Adjustment: Barclays has reduced the price target for Bicycle Therapeutics (BCYC) from $40 to $15 while maintaining an Overweight rating, citing increased caution and adjustments in their valuation approach.
Pipeline Confidence: Despite the price target cut, Barclays believes that the company's pipeline catalysts are still on track, indicating confidence in Bicycle Therapeutics' future developments.
Trade with 70% Backtested Accuracy
Analyst Views on BCYC
About BCYC
About the author
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Bicycle Therapeutics plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle from Outperform to Sector Perform, citing delays in dose selection for its drug in phase 2/3 development for metastatic urothelial cancer, pushing timelines to Q1 2026, which threatens its competitive position in a growing market.
- Increased Competition Impact: Timashev noted that any further delays from Bicycle will benefit competing products from Pfizer, potentially leading to a loss of market share and negatively impacting future revenue expectations.
- Stock Price Reaction: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price fell by $0.69, or 7.88%, closing at $8.07, reflecting market concerns regarding the company's outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bicycle Therapeutics plc and its executives, urging affected investors to reach out for assistance.
Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle's stock from Outperform to Sector Perform due to delays in the development of its cancer treatment, which may negatively impact its market position against competitors.
Stock Price Impact: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped by 7.88%, closing at $8.07 on October 31, 2025.
Pomerantz LLP Background: Pomerantz LLP is a well-established law firm specializing in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and achieving significant damages awards.
Citizens Upholds Outperform Rating for Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market
Analyst Recommendation: Citizens maintains a Market Outperform recommendation for Bicycle Therapeutics plc - Depositary Receipt (NasdaqGS:BCYC) as of October 31, 2025, with a projected one-year price target of $24.91/share, indicating a potential upside of 209.00% from its current price of $8.06/share.
Projected Revenue and EPS: The projected annual revenue for Bicycle Therapeutics is estimated at $48 million, reflecting a 146.60% increase, while the projected non-GAAP EPS is -4.30.
Fund Sentiment: There are 142 funds reporting positions in Bicycle Therapeutics, with a 10.94% increase in ownership over the last quarter. The average portfolio weight for these funds is 0.24%, which has increased by 18.04%.
Shareholder Activity: Notable shareholders include Baker Bros. Advisors, Fcpm Iii Services B.v., Armistice Capital, Westfield Capital Management Co, and Siren, L.L.C., with varying changes in their shareholdings and portfolio allocations over the last quarter.
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Bicycle Therapeutics plc has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle from Outperform to Sector Perform, citing delays in dose selection for its drug in phase 2/3 development for metastatic urothelial cancer, pushing timelines to Q1 2026, which threatens its competitive position in a growing market.
- Increased Competition Impact: Timashev noted that any further delays from Bicycle will benefit competing products from Pfizer, potentially leading to a loss of market share and negatively impacting future revenue expectations.
- Stock Price Reaction: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price fell by $0.69, or 7.88%, closing at $8.07, reflecting market concerns regarding the company's outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bicycle Therapeutics plc and its executives, urging affected investors to reach out for assistance.
Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle's stock from Outperform to Sector Perform due to delays in the development of its cancer treatment, which may negatively impact its market position against competitors.
Stock Price Impact: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped by 7.88%, closing at $8.07 on October 31, 2025.
Pomerantz LLP Background: Pomerantz LLP is a well-established law firm specializing in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and achieving significant damages awards.
Citizens Upholds Outperform Rating for Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market
Analyst Recommendation: Citizens maintains a Market Outperform recommendation for Bicycle Therapeutics plc - Depositary Receipt (NasdaqGS:BCYC) as of October 31, 2025, with a projected one-year price target of $24.91/share, indicating a potential upside of 209.00% from its current price of $8.06/share.
Projected Revenue and EPS: The projected annual revenue for Bicycle Therapeutics is estimated at $48 million, reflecting a 146.60% increase, while the projected non-GAAP EPS is -4.30.
Fund Sentiment: There are 142 funds reporting positions in Bicycle Therapeutics, with a 10.94% increase in ownership over the last quarter. The average portfolio weight for these funds is 0.24%, which has increased by 18.04%.
Shareholder Activity: Notable shareholders include Baker Bros. Advisors, Fcpm Iii Services B.v., Armistice Capital, Westfield Capital Management Co, and Siren, L.L.C., with varying changes in their shareholdings and portfolio allocations over the last quarter.
